Evidence map›Paper›PMID 22137124›Full record

ArticleBiomaterials2012

Plasmonic nanobubble-enhanced endosomal escape processes for selective and guided intracellular delivery of chemotherapy to drug-resistant cancer cells.

Ekaterina Y Lukianova-Hleb, Andrey Belyanin, Shruti Kashinath, Xiangwei Wu, Dmitri O Lapotko

Abstract read
In one paragraph

Article in Biomaterials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 118 citations in OpenAlex.

  1. Review
  2. Article
  3. Investigating the Potential of CONanomaterials (Basel, Switzerland) · 2024
    Article
  4. Review
  5. Article
  6. Multifunctional nanoclusters of NaYFMaterials science & engineering. C, Materials for biological applications · 2019
    Article
  7. Article
  8. Article
  9. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ekaterina Y Lukianova-HlebDepartment of Biochemistry and Cell Biology, Rice University, Houston, TX 77005, USA.
Andrey Belyanin
Shruti Kashinath
Xiangwei Wu
Dmitri O Lapotko
Rice University · USThe University of Texas MD Anderson Cancer Center · US

Funding

Cell Theranostics with Tunable Plasmonic NanobubblesR01GM094816 · NIGMS · RICE UNIVERSITY · PI LAPOTKO, DMITRI · 2010 to 2013
$1.1M
Laser scanning confocal microscopeS10RR026399 · NCRR · RICE UNIVERSITY · PI BARTEL, BONNIE · 2010 to 2010
$500k
NCRR NIH HHS S10 RR026399NCRR NIH HHS S10RR026399-01NIGMS NIH HHS R01 GM094816NIGMS NIH HHS R01GM094816
6 · The paper itself

Abstract

Cancer chemotherapies suffer from multi drug resistance, high non-specific toxicity and heterogeneity of tumors. We report a method of plasmonic nanobubble-enhanced endosomal escape (PNBEE) for the selective, fast and guided intracellular delivery of drugs through a self-assembly by cancer cells of separately targeted gold nanoparticles and encapsulated drug (Doxil). The co-localized with Doxil plasmonic nanobubbles optically generated in cancer cells released the drug into the cytoplasm thus increasing the therapeutic efficacy against these drug-resistant cells by 31-fold, reducing drug dose by 20-fold, the treatment time by 3-fold and the non-specific toxicity by 10-fold compared to standard treatment. Thus the PNBEE mechanism provided selective, safe and efficient intracellular drug delivery in heterogeneous environment opening new opportunities for drug therapies.

Indexed as

Antineoplastic AgentsCell Line, TumorCytoplasmDose-Response Relationship, DrugDoxorubicinDrug CarriersDrug Delivery SystemsGoldHumansLasersLiposomesMetal NanoparticlesNanoparticlesNanotechnologyNeoplasmsAntineoplastic AgentsDoxorubicinDrug CarriersGoldLiposomes

Identifiers

PMID22137124
PMCPMC3340418
OpenAlexW1991857713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.